SironRX spun out from Juventas Therapeutics and licenses products from its parent and Cleveland Clinic and will use the $500,000 seed money to initiate a phase II clinical study of its lead product.

Nomura will retain part of the assets in its Phase4 Ventures corporate venturing unit, with the rest sold to fund manager HarbourVest Partners.

Elenza's $24m B round came from private equity firm Carlyle Group, venture capital firm Delphi Ventures and an undisclosed strategic corporate investor from the ophthalmic industry, as well as Itochu.

IntegenX, formerly known as Microchip Biotechnologies, buys biotech peer GenVault and raises $15.6m.

Ascension Health Ventures leads $14m D round for Ocular Therapeutix.

Dutch healthcare investor Jonghoud International and Industrial Bank of Taiwan Management's Boston Life Science fund are new investors in To-BBB's $5.5m B round, alongside existing investors Aescap Venture and Antea Participaties.

George Siber, executive chairman of Genocea's board, said: "In Chip [Clark]'s short time at Genocea, he has proven himself to be a tremendous asset to the company" and the company said he "played a critical role in closing the company's $35m round of series B financing announced last month".

BG Medicine plans to list 4.75 million shares for $7 each at its initial public offering (IPO), although investment bank Lazard can sell a further 712,500 shares if demand is strong enough. The previous price range was $13 to $15 per share.